Late Effects of Hodgkin's Disease and Its Treatment

被引:39
|
作者
Ng, Andrea K.
Mauch, Peter M.
机构
[1] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
来源
CANCER JOURNAL | 2009年 / 15卷 / 02期
关键词
Hodgkin's lymphoma; late effects; complications; second malignant neoplasms; CORONARY-ARTERY-DISEASE; LAPAROSCOPIC OOPHOROPEXY; MEDIASTINAL IRRADIATION; OVARIAN-FUNCTION; 2ND MALIGNANCY; LUNG-CANCER; CHEMOTHERAPY; RADIOTHERAPY; LYMPHOMA; RISK;
D O I
10.1097/PPO.0b013e31819e30d7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Long-term survivors of Hodgkin's lymphoma are at increased risk for a number of late complications, including development of second malignancies and cardiovascular disease. Treatment-related factors and other modifying risk factors contributing to the risk of late effects have been identified. Survivors deemed at increased risk based on their treatment history and other exposures may benefit from early detection for late complications and risk reduction strategies. However, the optimal screening tests and prevention program, and their timing and frequency are not clear. It should be noted that treatment for Hodgkin's lymphoma has undergone considerable changes over the last several decades. Most of the current data on late effects after Hodgkin's lymphoma are based on patients treated with outdated chemotherapy and radiation therapy, As Hodgkin's lymphoma therapy evolve over time, continued documentation of late effects associated with newer treatment will be important for the follow-up of patients treated in the modern era.
引用
收藏
页码:164 / 168
页数:5
相关论文
共 50 条
  • [21] Late effects of therapy for Hodgkin's lymphoma
    Adams M.J.
    Constine L.S.
    Lipshultz S.E.
    Current Hematologic Malignancy Reports, 2007, 2 (3) : 143 - 150
  • [22] Hodgkin's disease: treatment of relapsed disease
    Cavalli, FG
    ANNALS OF ONCOLOGY, 2002, 13 : 159 - 162
  • [23] Late relapse after treatment for clinical stage I and II Hodgkin's disease
    Brierley, JD
    Rathmell, AJ
    Gospodarowicz, MK
    Sutcliffe, SB
    Pintillie, M
    CANCER, 1997, 79 (07) : 1422 - 1427
  • [24] Results of treatment in Hodgkin's disease
    Yates, JL
    Bunting, CH
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1917, 68 : 747 - 751
  • [25] Treatment of relapsed Hodgkin's disease
    Gause, BL
    Longo, DL
    BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (03): : 559 - 572
  • [26] Pathogenesis and treatment of Hodgkin's disease
    Tesch, H
    Bohlen, H
    Wolf, J
    Engert, A
    MEDIZINISCHE KLINIK, 1998, 93 (02) : 82 - 90
  • [27] Current treatment of Hodgkin's disease
    Eghbali, H
    Soubeyran, P
    Tchen, N
    de Mascarel, I
    Soubeyran, I
    Richaud, P
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 35 (01) : 49 - 73
  • [28] Hodgkin lymphoma: Late effects of treatment and guidelines for surveillance
    Ng, Andrea K.
    van Leeuwen, Flora E.
    SEMINARS IN HEMATOLOGY, 2016, 53 (03) : 209 - 215
  • [29] The rational treatment of Hodgkin's disease
    Yates, JL
    Bunting, CH
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1915, 64 : 1953 - 1961
  • [30] Primary treatment of Hodgkin's disease
    Canellos, GP
    ANNALS OF ONCOLOGY, 2002, 13 : 153 - 158